The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Investigating novel therapeutic approaches for T-cell lymphoma
In this video, Yumeng Zhang, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses novel therapies under investigation for T-cell lymphoma, emphasizing the need for effective, well-tolerated treatments. She mentions ropeginterferon alfa-2b, an interferon-based therapy currently under investigation in a Phase I/Ib trial (NCT07047885) in cutaneous T-cell lymphoma (CTCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
